AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17666349 — intervention group
Group type: EXPERIMENTAL
Intervention: Embryos with two pronuclei in close vicinity, central position of the pronuclei in the cytoplasm, and comparable size of the two pronuclei.
Number of subjects: 62
Study 17666349 — intervention group
Group type: EXPERIMENTAL
Intervention: Embryos developed from zygotes with linear arrangement of 3 to 7 NPB in moderate sizes.
Number of subjects: 62
Study 17666349 — intervention group
Group type: EXPERIMENTAL
Intervention: Zygotes with excessive cytoplasmic granularity.
Number of subjects: 62
Study 17666349 — intervention group
Group type: COMPARATOR
Intervention: Other morphologic characteristics (polar bodies, color of the cytoplasm, cytoplasm halo, or vacuoles in the cytoplasm).
Number of subjects: 62
Study 15826265 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone sodium phosphate
Number of subjects: 40
Study 15826265 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone acetate
Number of subjects: 40
Study 15826265 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone sodium phosphate and dexamethasone acetate
Number of subjects: 40
Study 11929350 — intervention group
Group type: EXPERIMENTAL
Intervention: Urokinase plus abciximab
Number of subjects: 70
Study 11929350 — intervention group
Group type: COMPARATOR
Intervention: Urokinase alone
Number of subjects: 70
Study 9506325 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium channel blockers
Number of subjects: 2120
Study 9506325 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium channel blockers (in SAVE placebo group)
Number of subjects: 2120
Study 9506325 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium channel blockers (in SAVE captopril group)
Number of subjects: 2120
Study 7918923 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentasa 2 g/day
Number of subjects: 13
Study 7918923 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentasa 4 g/day
Number of subjects: 13
Study 7918923 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentasa 6 g/day
Number of subjects: 13
Study 7918923 — intervention group
Group type: COMPARATOR
Intervention: Olsalazine 2 g/day
Number of subjects: 13
Study 7918923 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentasa 4 g/day and 6 g/day
Number of subjects: 13
Study 3137180 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine
Number of subjects: 20
Study 3137180 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 28875327 — intervention group
Group type: EXPERIMENTAL
Intervention: 200-μg selenium per day for 8 weeks
Number of subjects: 40
Study 28875327 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 28390695 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ramipril 10 mg/day (n=8407)
Number of subjects: 30937
Study 28390695 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral telmisartan 80 mg/day (n=8386)
Number of subjects: 30937
Study 28390695 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ramipril and telmisartan (n=8334)
Number of subjects: 30937
Study 28390695 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral telmisartan 80 mg/day (n=2903)
Number of subjects: 30937
Study 28390695 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=2907)
Number of subjects: 30937
Study 26301484 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Locus of Control questionnaire (HLOC)
Number of subjects: 60000
Study 26301484 — intervention group
Group type: EXPERIMENTAL
Intervention: HLOC plus AR questionnaire
Number of subjects: 60000
Study 26301484 — intervention group
Group type: COMPARATOR
Intervention: No questionnaire (control)
Number of subjects: 60000
Study 26301484 — intervention group
Group type: EXPERIMENTAL
Intervention: AR intervention
Number of subjects: 60000
Study 26301484 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary outcomes
Number of subjects: 60000
Study 23389687 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived stress
Number of subjects: 3759
Study 23389687 — intervention group
Group type: EXPERIMENTAL
Intervention: Life events
Number of subjects: 3759
Study 20490520 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive anterolateral approach (ALMI)
Number of subjects: 44
Study 20490520 — intervention group
Group type: COMPARATOR
Intervention: Modified direct lateral approach (mDL)
Number of subjects: 44
Study 20490520 — intervention group
Group type: COMPARATOR
Intervention: mDL
Number of subjects: 44
Study 18499604 — intervention group
Group type: EXPERIMENTAL
Intervention: Dex 0.2 microg x kg(‐1) x h(‐1) IV
Number of subjects: 80
Study 18499604 — intervention group
Group type: EXPERIMENTAL
Intervention: Dex 0.4 microg x kg(‐1) x h(‐1) IV
Number of subjects: 80
Study 18499604 — intervention group
Group type: EXPERIMENTAL
Intervention: Dex 0.8 microg x kg(‐1) x h(‐1) IV
Number of subjects: 80
Study 18499604 — intervention group
Group type: COMPARATOR
Intervention: Control group (saline infusion)
Number of subjects: 80
Study 16687898 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy
Number of subjects: 0
Study 16687898 — intervention group
Group type: EXPERIMENTAL
Intervention: Lead-induced obstruction in coronary sinus
Number of subjects: 0
Study 16687898 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac venous blood pumping conditions
Number of subjects: 0
Study 16687898 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal activation of left ventricle
Number of subjects: 0
Study 14534370 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger root (1 g)
Number of subjects: 22
Study 14534370 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 14534370 — intervention group
Group type: COMPARATOR
Intervention: Misoprostol (400 microg)
Number of subjects: 22
Study 10590490 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 0
Study 10590490 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers (e.g., carvedilol)
Number of subjects: 0
Study 10590490 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD therapy
Number of subjects: 0
Study 10590490 — intervention group
Group type: COMPARATOR
Intervention: EP guided therapy
Number of subjects: 0
Study 10590490 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 0
Study 8698943 — intervention group
Group type: EXPERIMENTAL
Intervention: Transference-oriented approach
Number of subjects: 60
Study 8698943 — intervention group
Group type: EXPERIMENTAL
Intervention: Transference focus
Number of subjects: 60
Study 8698943 — intervention group
Group type: EXPERIMENTAL
Intervention: High QOR sample
Number of subjects: 60
Study 1605660 — intervention group
Group type: EXPERIMENTAL
Intervention: Nystatin
Number of subjects: 73
Study 1605660 — intervention group
Group type: COMPARATOR
Intervention: Norfloxacin (800 mg, orally QID)
Number of subjects: 73
Study 6374774 — intervention group
Group type: COMPARATOR
Intervention: etidocaine 1.5% without a vasoconstrictor (n = 10)
Number of subjects: 30
Study 6374774 — intervention group
Group type: EXPERIMENTAL
Intervention: etidocaine 1.5% with adrenaline 1:200,000 (n = 10)
Number of subjects: 30
Study 6374774 — intervention group
Group type: EXPERIMENTAL
Intervention: etidocaine 1.5% with ornipressine 1 IU/10 ml (n = 10)
Number of subjects: 30
Study 30591358 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium reduction program (education and access to reduced-sodium salt substitute)
Number of subjects: 2566
Study 30591358 — intervention group
Group type: COMPARATOR
Intervention: Control group (no sodium reduction program)
Number of subjects: 2566
Study 30591358 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium reduction program
Number of subjects: 2566
Study 30017346 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 576
Study 30017346 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 576
Study 27503474 — intervention group
Group type: EXPERIMENTAL
Intervention: Typhoid polysaccharide vaccine
Number of subjects: 16
Study 27503474 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 16
Study 25252510 — intervention group
Group type: EXPERIMENTAL
Intervention: Eutectic Mixture of Local Anaesthetics cream (2g applied to injection site)
Number of subjects: 50
Study 25252510 — intervention group
Group type: EXPERIMENTAL
Intervention: Rattle (shaken for 30s to 15s before injection)
Number of subjects: 50
Study 25252510 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 50
Study 25252510 — intervention group
Group type: EXPERIMENTAL
Intervention: Eutectic Mixture of Local Anaesthetics cream
Number of subjects: 50
Study 25252510 — intervention group
Group type: EXPERIMENTAL
Intervention: Rattle
Number of subjects: 50
Study 25252510 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study 22149540 — intervention group
Group type: EXPERIMENTAL
Intervention: bidimensional-slot (bDS)
Number of subjects: 76
Study 22149540 — intervention group
Group type: EXPERIMENTAL
Intervention: bidimensional-wire (bDW)
Number of subjects: 76
Study 22149540 — intervention group
Group type: COMPARATOR
Intervention: control
Number of subjects: 76
Study 20876734 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP guided therapy
Number of subjects: 252
Study 20876734 — intervention group
Group type: COMPARATOR
Intervention: Guideline-based treatment
Number of subjects: 252
Study 18284057 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral holmium laser enucleation of the prostate (HoLEP)
Number of subjects: 60
Study 18284057 — intervention group
Group type: COMPARATOR
Intervention: Open prostatectomy
Number of subjects: 60
Study 18284057 — intervention group
Group type: EXPERIMENTAL
Intervention: Both HoLEP and open prostatectomy
Number of subjects: 60
Study 16119401 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive total hip replacement (< or = 10 cm)
Number of subjects: 219
Study 16119401 — intervention group
Group type: COMPARATOR
Intervention: Standard incision total hip replacement (16 cm)
Number of subjects: 219
Study 16119401 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive total hip replacement
Number of subjects: 219
Study 16119401 — intervention group
Group type: COMPARATOR
Intervention: Standard incision total hip replacement
Number of subjects: 219
Study 12379391 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate active mobilisation
Number of subjects: 60
Study 12379391 — intervention group
Group type: COMPARATOR
Intervention: Delayed mobilisation (5-day delay)
Number of subjects: 60
Study 10027027 — intervention group
Group type: EXPERIMENTAL
Intervention: Dixyrazine 0.25 mg kg‐1
Number of subjects: 60
Study 10027027 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 7738924 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonstress test (NST) during the 41st week of pregnancy
Number of subjects: 300
Study 7738924 — intervention group
Group type: COMPARATOR
Intervention: Control group (no NST)
Number of subjects: 300
Study 2290245 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (received letter with colorectal cancer facts and Risk Appraisal)
Number of subjects: 278
Study 2290245 — intervention group
Group type: COMPARATOR
Intervention: Control group (received letter stating availability of FOB test)
Number of subjects: 278
Study 7015021 — intervention group
Group type: EXPERIMENTAL
Intervention: Minidose propranolol (5 to 10 mg/6 hr)
Number of subjects: 85
Study 7015021 — intervention group
Group type: COMPARATOR
Intervention: Control (no propranolol)
Number of subjects: 85
Study 7015021 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol postoperatively (not specified dosage)
Number of subjects: 85
Study 30724634 — intervention group
Group type: EXPERIMENTAL
Intervention: Male firstness in academic writing
Number of subjects: 754
Study 30724634 — intervention group
Group type: COMPARATOR
Intervention: Female firstness in academic writing
Number of subjects: 754
Study 31106574 — intervention group
Group type: EXPERIMENTAL
Intervention: EasyWarm® self-heating blanket
Number of subjects: 39
Study 31106574 — intervention group
Group type: COMPARATOR
Intervention: Cocoon forced-air warming blanket
Number of subjects: 39
Study 28853509 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 60
Study 28853509 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-remifentanil
Number of subjects: 60
Study 26378246 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine consumption equivalent to a double espresso 3 hours before habitual bedtime
Number of subjects: 49
Study 26378246 — intervention group
Group type: COMPARATOR
Intervention: Evening bright light exposure (3000 lux, 7 W/m(2))
Number of subjects: 49
Study 26378246 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (dose-dependent)
Number of subjects: 49
Study 26378246 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 49
Study 22879443 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy and spine strengthening exercises
Number of subjects: 149
Study 21884875 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR(CKD‐EPI)
Number of subjects: 14527
Study 21884875 — intervention group
Group type: COMPARATOR
Intervention: eGFR(MDRD)
Number of subjects: 14527
Study 20057194 — intervention group
Group type: EXPERIMENTAL
Intervention: Water consumption promotion intervention (water fountains installed, water bottles provided, classroom lessons conducted)
Number of subjects: 2950
Study 20057194 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 2950
Study 20057194 — intervention group
Group type: EXPERIMENTAL
Intervention: Water consumption promotion intervention
Number of subjects: 2950
Study 17130429 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine as monotherapy
Number of subjects: 0
Study 17130429 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate as monotherapy
Number of subjects: 0
Study 17130429 — intervention group
Group type: COMPARATOR
Intervention: Immediate antiepileptic drug treatment
Number of subjects: 0
Study 17130429 — intervention group
Group type: COMPARATOR
Intervention: Delayed antiepileptic drug treatment
Number of subjects: 0
Study 15276508 — intervention group
Group type: EXPERIMENTAL
Intervention: On-pump coronary artery bypass grafting (n = 26)
Number of subjects: 52
Study 15276508 — intervention group
Group type: COMPARATOR
Intervention: Off-pump coronary artery bypass grafting (n = 26)
Number of subjects: 52
Study 11039455 — intervention group
Group type: EXPERIMENTAL
Intervention: 201Tl myocardial SPET with exercise (n = 9)
Number of subjects: 22
Study 11039455 — intervention group
Group type: EXPERIMENTAL
Intervention: 201Tl myocardial SPET with dipyridamole stress (n = 13)
Number of subjects: 22
Study 11039455 — intervention group
Group type: COMPARATOR
Intervention: Group A (n = 10) with cardiac abnormalities on conventional testing
Number of subjects: 22
Study 11039455 — intervention group
Group type: COMPARATOR
Intervention: Group B (n = 12) without cardiac abnormalities on conventional testing
Number of subjects: 22
Study 9292072 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 alpha,25(OH)2D3 (calcitriol)
Number of subjects: 42
Study 9292072 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol
Number of subjects: 42
Study 9292072 — intervention group
Group type: EXPERIMENTAL
Intervention: KH 1060 (lexacalcitol)
Number of subjects: 42
Study 9292072 — intervention group
Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid
Number of subjects: 42
Study 9292072 — intervention group
Group type: COMPARATOR
Intervention: Sodium lauryl sulphate (SLS)
Number of subjects: 42
Study 9292072 — intervention group
Group type: COMPARATOR
Intervention: Solution vehicles and empty chamber
Number of subjects: 42
Study 8111209 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvia miltiorrhizae and Polyporus Umbellatus polysaccharide (group I)
Number of subjects: 90
Study 8111209 — intervention group
Group type: COMPARATOR
Intervention: Salvia miltiorrhizae (group II)
Number of subjects: 90
Study 8111209 — intervention group
Group type: COMPARATOR
Intervention: Polyporus Umbellatus polysaccharide (group III)
Number of subjects: 90
Study 3518596 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxymesterone (synthetic androgen) for 3 days before and on the day of chemotherapy
Number of subjects: 57
Study 3518596 — intervention group
Group type: COMPARATOR
Intervention: Cyclic chemotherapy with aminoglutethimide and hydrocortisone
Number of subjects: 57
Study 3518596 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 57
Study 3518596 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation group
Number of subjects: 57
Study 31482511 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin 5 mg qd
Number of subjects: 102
Study 31482511 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 29934384 — intervention group
Group type: EXPERIMENTAL
Intervention: Low birth weight infants (LBW)
Number of subjects: 44984
Study 25190537 — intervention group
Group type: EXPERIMENTAL
Intervention: Raising the bed head
Number of subjects: 24
Study 25190537 — intervention group
Group type: EXPERIMENTAL
Intervention: Using multiple pillows
Number of subjects: 24
Study 25190537 — intervention group
Group type: COMPARATOR
Intervention: Sitting position
Number of subjects: 24
Study 22520267 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose to the anal surface at 53 Gy
Number of subjects: 388
Study 22520267 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean dose to the anal surface
Number of subjects: 388
Study 19669773 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracorporeal pneumatic shock therapy (IPST)
Number of subjects: 50
Study 19669773 — intervention group
Group type: COMPARATOR
Intervention: Inactive (placebo)
Number of subjects: 50
Study 17558730 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and activity advice (low-fat, high-carbohydrate, sucrose-containing diet + 60 min/day brisk walking)
Number of subjects: 69
Study 17558730 — intervention group
Group type: COMPARATOR
Intervention: Low-fat, high-carbohydrate (including sucrose) energy-reduced diet
Number of subjects: 69
Study 17558730 — intervention group
Group type: COMPARATOR
Intervention: 60 min/day brisk walking
Number of subjects: 69
Study 16178960 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal manipulative therapy
Number of subjects: 2
Study 12227275 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (Verteporfin)
Number of subjects: 46
Study 12227275 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 9863775 — intervention group
Group type: EXPERIMENTAL
Intervention: Pb glazing families (exposed to lead)
Number of subjects: 51
Study 9863775 — intervention group
Group type: COMPARATOR
Intervention: Non-Pb glazing families (not exposed to lead)
Number of subjects: 51
Study 8550248 — intervention group
Group type: EXPERIMENTAL
Intervention: CoQ10 (150 mg/day for 2 months)
Number of subjects: 15
Study 8550248 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 months)
Number of subjects: 15
Study 2693917 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal 17 beta-estradiol (Estraderm)
Number of subjects: 46
Study 2693917 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 46
Study 335279 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (1000 mg/day)
Number of subjects: 50
Study 31880370 — intervention group
Group type: EXPERIMENTAL
Intervention: Kisspeptin-10 (Kp10) injection (5 µg/kg body weight), administered intramuscularly once a week for 1 month
Number of subjects: 0
Study 31880370 — intervention group
Group type: COMPARATOR
Intervention: Saline-treated control group
Number of subjects: 0
Study 30935545 — intervention group
Group type: EXPERIMENTAL
Intervention: Propolis (500 mg, three times a day for 8 weeks)
Number of subjects: 62
Study 30935545 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 29145288 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold application (600-g ice packs for 15 minutes before CTR)
Number of subjects: 60
Study 29145288 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (tap water packs)
Number of subjects: 60
Study 29145288 — intervention group
Group type: COMPARATOR
Intervention: Both experimental and sham groups (men)
Number of subjects: 60
Study 25990355 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 58
Study 25990355 — intervention group
Group type: COMPARATOR
Intervention: Zoledronic acid
Number of subjects: 58
Study 23053900 — intervention group
Group type: EXPERIMENTAL
Intervention: Mosapride (30 mg) plus esomeprazole (40 mg)
Number of subjects: 50
Study 23053900 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus esomeprazole (40 mg)
Number of subjects: 50
Study 21600117 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension-free vaginal tape (TVT)
Number of subjects: 315
Study 21600117 — intervention group
Group type: COMPARATOR
Intervention: Transobturator tape (TVT-O)
Number of subjects: 315
Study 18752430 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetanus toxoid (TT) vaccine
Number of subjects: 46
Study 18752430 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis A virus (HAV) vaccine
Number of subjects: 46
Study 18752430 — intervention group
Group type: COMPARATOR
Intervention: Control group (received TT vaccine first, then HAV vaccine)
Number of subjects: 46
Study 15895329 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength Training and Stretching (STG)
Number of subjects: 126
Study 15895329 — intervention group
Group type: COMPARATOR
Intervention: Stretching Alone (CG)
Number of subjects: 126
Study 15895329 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength Training (STG)
Number of subjects: 126
Study 15895329 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Groups
Number of subjects: 126
Study 12022799 — intervention group
Group type: EXPERIMENTAL
Intervention: Voucher (n = 29)
Number of subjects: 52
Study 12022799 — intervention group
Group type: COMPARATOR
Intervention: No-voucher (n = 23)
Number of subjects: 52
Study 10093094 — intervention group
Group type: EXPERIMENTAL
Intervention: ISAAC study (Brazil)
Number of subjects: 0
Study 10093094 — intervention group
Group type: EXPERIMENTAL
Intervention: Portuguese Study (Cape Verde)
Number of subjects: 0
Study 10093094 — intervention group
Group type: EXPERIMENTAL
Intervention: Portuguese Study (Madeira)
Number of subjects: 0
Study 10093094 — intervention group
Group type: EXPERIMENTAL
Intervention: Portuguese Study (Macau)
Number of subjects: 0
Study 10093094 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchial challenge test
Number of subjects: 0